New antibody drug targets Hard-to-Treat cancers in first human trial
Disease control
Recruiting now
This early-phase study tests a new drug called CBA-1205, an antibody that targets a protein (DLK1) found on some cancer cells. The main goal is to check safety and find the right dose in about 66 adults with advanced solid tumors, including liver cancer and melanoma. Participants…
Phase: PHASE1 • Sponsor: Chiome Bioscience Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC